amoxi * tabs (amoxicillin tablets), USP

Veterinary Tablets

For use in dogs and cats

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Amoxi-Tabs (amoxicillin tablets) is a semi-synthetic antibiotic with a broad spectrum of activity. It provides bactericidal activity against a wide range of common gram-positive and gramnegative pathogens. Chemically, it is D(-)- α -amino-p-hydroxy-benzyl penicillin trihydrate.

CLINICAL PHARMACOLOGY: Amoxi-Tabs is stable in the presence of gastric acid and may be given without regard to meals. It is rapidly absorbed after oral administration. It diffuses readily into most body tissues and fluids with the exception of brain and spinal fluid, except when meninges are inflamed. Most of the amoxicillin is excreted unchanged in the urine.

Amoxicillin is similar to ampicillin in its bactericidal action against susceptible organisms. It acts through the inhibition of biosynthesis of cell wall mucopeptide. In vitro and/or in vivo studies have demonstrated the susceptibility of most strains of the following gram-positive and gram-negative bacteria: α - and β -haemolytic streptococci, nonpenicillinase-producing staphylococci, Streptococcus faecalis, Escherichia coli, and Proteus mirabilis. Because it does not resist destruction by penicillinase, it is not effective against penicillinase-producing bacteria, particularly resistant staphylococci. All strains of Pseudomonas and most strains of Klebsiella and Enterobacter are resistant.

INDICATIONS AND USAGE:

Proteus mirabilis.

Dogs: Amoxi-Tabs are indicated in the treatment of susceptible strains of the organisms causing the following infections:

Respiratory tract infections (tonsillitis, tracheobronchitis) due to Staphylococcus aureus, Streptococcus spp., E. coli,

and *Proteus mirabilis*.

Genitourinary tract infections (cystitis) due to *Staphylococcus aureus*, *Streptococcus* spp., *E. coli*, and *Proteus mirabilis*.

Gastrointestinal tract infections (bacterial gastroenteritis) due to *Staphylococcus aureus*, *Streptococcus* spp., *E. coli*, and

Bacterial dermatitis due to *Staphylococcus aureus*, *Streptococcus* spp., and *Proteus mirabilis*.

Soft tissue infections (abscesses, lacerations, and wounds) due to *Staphylococcus aureus*, *Streptococcus* spp., *E. coli*, and *Proteus mirabilis*.

Cats: Amoxi-Tabs are indicated in the treatment of susceptible strains of the organisms causing the following infections:

Upper respiratory tract infections due to *Staphylococcus aureus*, *Streptococcus* spp., and *E. coli*.

Genitourinary tract infections (cystitis) due to *Staphylococcus aureus*, *Streptococcus* spp., *E. coli*, and *Proteus mirabilis*.

Gastrointestinal tract infections due to E. coli.

Skin and soft tissue infections (abscesses, lacerations, and wounds) due to *Staphylococcus aureus, Streptococcus* spp., *E. coli*, and *Pasteurella multocida*.

As with all antibiotics, appropriate *in vitro* culturing and susceptibility testing of samples taken before treatment should be conducted.

CONTRAINDICATIONS: The use of this drug is contraindicated in animals with a history of an allergic reaction to penicillin.

WARNING: For use in dogs and cats only.

ADVERSE REACTIONS: Amoxicillin is a semisynthetic penicillin and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.

DOSAGE AND ADMINISTRATION:

Dogs: The recommended dosage is 5 mg/lb of body weight twice a day. Cats: The recommended dosage is 50 mg (5–10 mg/lb) once a day. Dosage should be continued for 5–7 days or 48 hours after all symptoms have subsided. If no improvement is seen in 5 days, review diagnosis and change therapy.

Do Not Store at Temperatures Above 25°C (77°F) Keep Bottle Tightly Closed.

HOW SUPPLIED: Amoxi-Tabs are supplied in 5 strengths: 50 mg, 100 mg, 150 mg, and 200 mg in bottles of 500 tablets; 400 mg in bottles of 250 tablets.

Approved by FDA under NADA # 055-078 Approved by FDA under NADA # 055-081



P1523357A&P Revised: January 2020